Amneal Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 4 analysts polled by S&P Global, Amneal Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $17.25. The average 1-year stock price forecast is 7.08% higher than the current stock price, while the lowest is $16 (-0.68%) and the highest is $19 (+17.94%).

Price Target: $17.25 (+7.08%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$16	$17.25	$17	$19
Change	-0.68%	+7.08%	+5.52%	+17.94%

Analyst Ratings

The average analyst rating for Amneal Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	2	2	2	3	3	2
Buy	3	3	3	2	2	2
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	5	5	5	5	5	4

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Ashwani Verma UBS	UBS	Buy Reiterates n/a	Buy	Reiterates	n/a	n/a	Jun 12, 2026
Glen Santangelo Barclays	Barclays	Buy Maintains $16	Buy	Maintains	$16	-0.68%	Jun 11, 2026
David Amsellem Piper Sandler	Piper Sandler	Buy Maintains $17	Buy	Maintains	$17	+5.52%	Jun 4, 2026
Matthew Dellatorre Goldman Sachs	Goldman Sachs	Buy Reiterates $17	Buy	Reiterates	$17	+5.52%	May 28, 2026
Les Sulewski Truist Financial	Truist Financial	Buy Maintains n/a	Buy	Maintains	n/a	n/a	Apr 23, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

3.11B

from 3.02B

2.89%

from 3.02B

Revenue Next Year

3.33B

from 3.11B

7.19%

from 3.11B

EPS This Year

0.99

from 0.83

18.93%

from 0.83

EPS Next Year

1.12

from 0.99

13.79%

from 0.99

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	2.09B	2.21B	2.39B	2.79B	3.02B	3.11B
Revenue Growth	5.08%	5.67%	8.20%	16.73%	8.05%	2.89%
Gross Profit	783.95M	791.46M	852.87M	1.02B	1.13B	1.41B
Gross Margin	37.44%	35.78%	35.63%	36.35%	37.38%	45.50%
Operating Income	216.60M	200.03M	260.38M	348.36M	420.70M	691.57M
Net Income	10.62M	-129.99M	-83.99M	-116.89M	72.06M	112.69M
EPS	-	-	-	-	0.83	0.99
EPS Growth	-	-	-	-	43.10%	18.93%
Forward PE	5.65	2.71	11.92	11.69	15.04	16.32
Free Cash Flow	217.65M	120.14M	300.39M	253.45M	197.07M	200.39M
No. Analysts	-	-	-	-	-	4

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	3.1B
Avg	3.1B
Low	3.1B

Revenue Growth

Revenue Growth	2026	2027	2028
High	3.7%
Avg	2.9%
Low	2.2%

EPS Forecast

EPS	2026	2027	2028
High	1.01
Avg	0.99
Low	0.94

EPS Growth

EPS Growth	2026	2027	2028
High	21.5%
Avg	18.9%
Low	13.1%